BridgeBio reports Q4 Attruby revenue $146M, cash $587.5M; plans two NDAs in H1 2026

BridgeBio Pharma, Inc.

Preliminary unaudited Q4 2025 Attruby net revenue $146M; full year $362.4M; cash, equivalents and securities $587.5M as of Dec 31, 2025.
6,629 unique patient prescriptions for Attruby written by 1,632 prescribers as of Dec 31, 2025, reflecting rapid adoption.
New TTR amyloid depleter antibody program to explore ATTR-CM disease reversal; clinic expected between 2027-2028.
FDA recommends NDA for BBP-418 (LGMD2I/R9) toward full approval after positive FORTIFY interim; submission planned H1 2026.
Encumeret NDA for ADH1 planned H1 2026; Phase 3 RECLAIM-HP in chronic hypoparathyroidism to start summer 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.